Use of the composition

Abstract

The present application relates to the use of a composition, for example the use of a composition in the manufacture of a product for improving eczema, wherein the composition comprises medium-long chain fatty acid triglycerides and partially hydrolyzed whey protein, wherein the mass ratio of the medium-long chain fatty acid triglycerides to the partially hydrolyzed whey protein is 0.167:1 to 6:1, and the degree of hydrolysis of the partially hydrolyzed whey protein is 7% to 25%. The eczema includes allergic eczema. The composition has a synergistic effect in improving eczema.

Description

Technical Field

[0001] This application relates to the use of the composition, and in particular to its use in the preparation of products for improving eczema. Background Technology

[0002] Allergic diseases are a group of diseases caused by abnormal or excessive reactions of the immune system to normally harmless environmental antigens (such as pollen, dust mites, food proteins, etc.). These diseases have a clear age-dependent evolutionary pattern, the so-called "atopic process", which is characterized by atopic dermatitis (eczema) in early life, which may then develop into allergic rhinitis, asthma and food allergies (Duan Su, Zhang Yuan, Zhang Luo. The natural process and intervention of allergic diseases [J]. Journal of Capital Medical University, 2011, 32(01):55-59).

[0003] Eczema has a high incidence rate in both adults and children. Itching is the most common symptom of eczema (Zhao Jian, Zhuo Fenglin, Li Linfeng. A nationwide multicenter cross-sectional survey of patients with eczema and dermatitis [J]. Journal of Clinical and Experimental Medicine, 2019, 18(07):736-741). Repeated itching and scratching can cause skin damage, secondary infection, pigmentation and other conditions, causing serious physical and psychological suffering to patients. Mast cells (MCs) play a central role in type I hypersensitivity reactions (i.e., immediate-type anaphylaxis), primarily triggering degranulation through a signaling cascade mediated by high-affinity IgE receptors (FcεRI). This releases inflammatory mediators such as proteases and cytokines, leading to typical allergic symptoms such as vasodilation, smooth muscle contraction, mucus secretion, and itching (Li Min, Zhou Jian, Jiang Chunlei. Research progress on IgE-mediated mast cell degranulation signal transduction pathway [J]. Modern Biomedical Progress, 2009, 9(18):3539-3541+3535). Topical corticosteroids are the first-line treatment for eczema, primarily exerting their effects through anti-inflammatory action. However, long-term or improper use can lead to local side effects such as skin atrophy, telangiectasia, and pigmentation, especially on the face and in skin folds where the risk is higher.

[0004] In conclusion, there is still a need in this field to develop safe and effective solutions for allergy relief and eczema improvement. Summary of the Invention

[0005] This application is made in view of the aforementioned problems existing in the prior art.

[0006] In one aspect, this application relates to the use of a composition in the preparation of a product for improving eczema, the composition comprising medium- and long-chain fatty acid triglycerides and partially hydrolyzed whey protein, wherein the mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed whey protein is from 0.167:1 to 6:1, and the degree of hydrolysis of the partially hydrolyzed whey protein is from 7% to 25%.

[0007] In some embodiments, the eczema is allergic eczema.

[0008] In some embodiments, the mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein is from 0.333:1 to 6:1.

[0009] In some embodiments, the mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein is from 0.667:1 to 6:1.

[0010] In some embodiments, the mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein is from 1:1 to 6:1.

[0011] In some embodiments, the degree of hydrolysis of the partially hydrolyzed protein is 7% to 17%.

[0012] In some embodiments, the degree of hydrolysis of the partially hydrolyzed protein is 7% to 15%.

[0013] In some embodiments, the improvement of eczema includes one or more of reducing trypsin levels and relieving itching.

[0014] The beneficial effects of this application include: when medium- and long-chain fatty acid triglycerides are used in combination with partially hydrolyzed protein in a specific mass ratio, they exhibit a synergistic effect in relieving allergies and / or improving eczema, especially relieving itching and reducing trypsin levels. The combined effect is superior to the effect of using the same amount of medium- and long-chain fatty acid triglycerides alone or using the same amount of partially hydrolyzed protein alone, and is also superior to the sum of the effects of using the same amount of medium- and long-chain fatty acid triglycerides alone and using the same amount of partially hydrolyzed protein alone.

[0015] For example, when long-chain fatty acid triglycerides and partially hydrolyzed proteins are used in combination at a ratio of 0.167:1 to 6:1, the composition can synergistically relieve itching and / or reduce trypsin levels, thereby alleviating allergies and / or improving eczema. Preferably, when long-chain fatty acid triglycerides and partially hydrolyzed proteins are used in combination at a mass ratio of 0.333:1 to 6:1, more preferably 0.667:1 to 6:1, and even more preferably 1:1 to 6:1, the composition can further synergistically relieve itching and / or reduce trypsin levels, thereby alleviating allergies and / or improving eczema. Attached Figure Description

[0016] To more clearly illustrate the technical solutions of this application, the accompanying drawings required for describing the embodiments will be briefly described below. It should be understood that these drawings are only for the purpose of facilitating a better understanding of this application by those skilled in the art, and are not intended to limit the scope of this application.

[0017] Figure 1 The graph shows the statistical content of trypsin in zebrafish after sample treatment, where compared with the model control group, This indicates that p < 0.05. This indicates that p < 0.01. This indicates that p < 0.001;

[0018] Figure 2 A typical graph of the total movement distance of zebrafish after sample treatment is shown, in which the black line represents the slow movement distance, the green line represents the medium movement distance, and the red line represents the fast movement distance; Figure 3 The graph shows the total movement distance of zebrafish after sample treatment, where, compared with the model control group, This indicates that p < 0.05. This indicates that p < 0.01. This means p < 0.001. Detailed Implementation

[0019] To provide a clearer understanding of the technical features, objectives, and beneficial effects of this application, the technical solution of this application is described in detail below with reference to specific embodiments and accompanying drawings. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of this application. Unless otherwise specifically defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Furthermore, unless otherwise stated, all methods, steps, techniques, and operations not specifically detailed can and have been performed in a manner commonly known and understood by one of ordinary skill in the art.

[0020] Composition

[0021] In one aspect, this application provides the use of a composition in the preparation of a product for relieving allergies and / or improving eczema, said composition comprising medium- and long-chain fatty acid triglycerides and partially hydrolyzed protein, wherein the mass ratio of said medium- and long-chain fatty acid triglycerides to said partially hydrolyzed protein is from 0.167:1 to 6:1. The inventors have surprisingly discovered that when the composition comprises medium- and long-chain fatty acid triglycerides and partially hydrolyzed protein in the above-mentioned ratio, it has a synergistic effect in relieving allergies and / or improving eczema.

[0022] As used herein, the term "medium-chain triglyceride" (MLCT) refers to a special type of triglyceride with a molecular structure containing both medium-chain and long-chain fatty acid residues. As used herein, the term "medium-chain fatty acid" refers to fatty acids with 6 to 12 carbon atoms in their carbon chain, such as hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, and dodecanoic acid. As used herein, the term "long-chain fatty acid" refers to fatty acids with 14 or more carbon atoms in their carbon chain, such as 14 to 30 carbon atoms, such as myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid. As used herein, the terms "medium-chain triglyceride" (MCT) and "long-chain triglyceride" (LCT) refer to the esterification products of medium-chain fatty acids and long-chain fatty acids with glycerol, respectively.

[0023] Medium- and long-chain fatty acid triglycerides, as a novel type of structured lipid, have attracted widespread attention. Their fatty acid composition is close to that of breast milk, which is beneficial for fat digestion and absorption. They can improve the absorption of lipid nutrients, inhibit the accumulation of body fat, and provide rapid and stable energy (Cheng, X). et al. Medium- and Long-Chain Triacylglycerol: Preparation, Health Benefits, and Food Utilization, Annu. Rev. Food Sci. Technol. 2024, 15, 381–408). Medium- and long-chain triglycerides have different physicochemical properties, metabolic characteristics, and nutritional value than long-chain or medium-chain triglycerides. Studies have shown that medium- and long-chain triglycerides are not simply equivalent to a physical mixture of long-chain and medium-chain triglycerides; the latter does not possess the physicochemical properties, metabolic characteristics, and nutritional value of the former (Yuan Tinglan. Composition and Metabolic Characteristics of Medium- and Long-Chain Triglycerides in Breast Milk Fat [D]. Wuxi: Jiangnan University, 2021).

[0024] As is known in the art, medium- and long-chain fatty acid triglycerides are produced by using edible vegetable oils and medium-chain triglycerides as raw materials, through transesterification reaction by lipase, followed by processes such as distillation, decolorization, and deodorization.

[0025] This application does not have any particular requirements regarding the medium- and long-chain fatty acid triglycerides used; any medium- and long-chain fatty acid triglycerides commonly used in the art can be used. Medium- and long-chain fatty acid triglycerides can be used in pure form or in a non-pure form rich in medium- and long-chain fatty acid triglycerides. For example, the medium- and long-chain fatty acid triglycerides used in the compositions of this application can be medium- and long-chain fatty acid triglycerides having a single composition (i.e., each molecular chain has the same long-chain fatty acid residues and the same medium-chain fatty acid residues), or a mixture of medium- and long-chain fatty acid triglycerides having two or more different compositions (i.e., each molecular chain has different long-chain fatty acid residues and / or different medium-chain fatty acid residues).

[0026] In some embodiments, the medium- and long-chain fatty acid triglycerides used in this application may contain C6-C6. 12 (e.g., C6, C7, C8, C9, C) 10 C 11 C 12 (or the range defined by either or both) fatty acid residues and C 14 ~C 30 (e.g., C) 14 C 15 C 16 C 17 C 18 C 19 C 20 C 21 C 22 C 23 C 24 C 25 C 26 C 27 C 28 C 29 C 30 (or the range defined by either C6-C6) fatty acid residues. In some examples, C6-C6... 12 Fatty acid residues can originate from one or more of the following: hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, and lauric acid, etc. C 14 ~C 30 Fatty acid residues can be derived from one or more of the following: myristic acid, palmitic acid, heptadecanic acid, oleic acid, linoleic acid, stearic acid, nonadecanic acid, eicosapentaenoic acid, docosahexaenoic acid, docosapatraenoic acid, docosahexaenoic acid, tricarboxylic acid, tetracarboxyenoic acid, docosapentaenoic acid, docosahexaenoic acid, arachidonic acid, etc. In some examples, C6~C... 12 The fatty acid residues may be derived from one or more of the following: hexanoic acid, caprylic acid, decanoic acid, and lauric acid. In some examples, C... 14 ~C 30Fatty acid residues may be derived from one or more of the following: myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid.

[0027] In some embodiments, the medium- and long-chain fatty acid triglycerides have C6~C6... 12 Fatty acid residues and C 14 ~C 30 The unit weight ratio of fatty acid residues can be from 0.124 to 2.000. For example, in the medium-chain fatty acid triglycerides, C6~C6... 12 Fatty acid residues and C 14 ~C 30 The unit weight ratio of fatty acid residues may be 0.124, 0.125, 0.130, 0.140, 0.150, 0.160, 0.170, 0.180, 0.190, 0.200, 0.300, 0.400, 0.500, 0.600, 0.700, 0.800, 0.900, 1.000, 1.100, 1.200, 1.300, 1.400, 1.500, 1.600, 1.700, 1.800, 1.900, 2.000, or within the range defined by any two of these.

[0028] As used herein, the term "partially hydrolyzed protein" may include partially hydrolyzed animal protein and / or partially hydrolyzed plant protein. In some embodiments, the partially hydrolyzed protein may be a partially hydrolyzed plant protein, which may be one or more selected from soy protein, pea protein, wheat protein, and rice protein. In some embodiments, the partially hydrolyzed protein may be a partially hydrolyzed animal protein, such as partially hydrolyzed milk protein (i.e., partially hydrolyzed cow's milk protein), wherein the milk protein is selected from whey protein, casein, or mixtures thereof, preferably whey protein. Preferably, the partially hydrolyzed protein is derived from demineralized whey powder. Preferably, the partially hydrolyzed protein may be partially hydrolyzed whey protein.

[0029] In some embodiments, the degree of hydrolysis of the partially hydrolyzed protein can be from 7% to 25%; within this range, the composition is more effective in relieving allergies and / or improving eczema. Preferably, the degree of hydrolysis of the partially hydrolyzed protein is from 7% to 17%; within this range, the composition is more effective in relieving allergies and / or improving eczema. Preferably, the degree of hydrolysis of the partially hydrolyzed protein is from 7% to 15%; within this range, the composition is more effective in relieving allergies and / or improving eczema.

[0030] In some embodiments, peptides with a molecular weight >5000 Da constitute 10% to 80% of the mass of the partially hydrolyzed protein; within this range, the composition is more effective in relieving allergies and / or improving eczema. In the partially hydrolyzed protein, the proportion of peptides with a molecular weight >5000 Da is, for example, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, or within the range defined by any two of these. Preferably, in the partially hydrolyzed protein, peptides with a molecular weight >5000 Da account for 10% to 70% by mass; within this range, the composition is more effective in relieving allergies and / or improving eczema.

[0031] In some embodiments, the peptides with a molecular weight of 1000 Da to 5000 Da constitute 7% to 47% by mass of the partially hydrolyzed protein; within this range, the composition is more effective in relieving allergies and / or improving eczema. The proportion of peptides with a molecular weight of 1000 Da to 5000 Da in the partially hydrolyzed protein is, for example, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, or within the range defined by any two of these. Preferably, in the partially hydrolyzed protein, peptides with a molecular weight of 1000 Da to 5000 Da account for 10% to 35% by mass; within this range, the composition is more effective in relieving allergies and / or improving eczema.

[0032] In some embodiments, peptides with a molecular weight <1000 Da constitute 13% to 80% of the mass of the partially hydrolyzed protein; within this range, the composition is more effective in relieving allergies and / or improving eczema. In the partially hydrolyzed protein, the proportion of peptides with a molecular weight <1000 Da is, for example, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, or within the range defined by any two of these. Preferably, in the partially hydrolyzed protein, peptides with a molecular weight <1000 Da account for 15% to 58% by mass; within this range, the composition is more effective in relieving allergies and / or improving eczema.

[0033] In some preferred embodiments, the degree of hydrolysis of the partially hydrolyzed protein is 7% to 15%, the proportion of peptides with a molecular weight > 5000 Da is 10% to 70% by mass, the proportion of peptides with a molecular weight of 1000-5000 Da is 10% to 35% by mass, and the proportion of peptides with a molecular weight < 1000 Da is 15% to 58% by mass; within this range, the composition is more effective in relieving allergies and / or improving eczema.

[0034] The partially hydrolyzed protein may be a single partially hydrolyzed protein or a mixture of two or more partially hydrolyzed proteins.

[0035] Currently, there is no literature reporting whether partially hydrolyzed proteins can alleviate allergies and / or improve eczema; and whether medium- and long-chain fatty acid triglycerides can be used in combination with partially hydrolyzed proteins to synergistically alleviate allergies and / or improve eczema requires further research.

[0036] In some embodiments of the compositions described in this application, the mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein is from 0.167:1 to 6:1. When the medium- and long-chain fatty acid triglycerides and the partially hydrolyzed protein are used in combination at mass ratios within the above range, the compositions can exhibit a significant synergistic effect, synergistically relieving allergies and / or improving eczema.

[0037] Preferably, the mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein can be from 0.333:1 to 6:1; when the medium- and long-chain fatty acid triglycerides and the partially hydrolyzed protein are used in combination at the mass ratio within the above range, the composition can show a more significant synergistic effect and can further synergistically relieve allergies and / or improve eczema.

[0038] More preferably, the mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein can be from 0.667:1 to 6:1; when the medium- and long-chain fatty acid triglycerides and the partially hydrolyzed protein are used in combination at the mass ratio within the above range, the composition can exhibit a more significant synergistic effect and can further synergistically relieve allergies and / or improve eczema.

[0039] More preferably, the mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein can be from 1:1 to 6:1; when the medium- and long-chain fatty acid triglycerides and the partially hydrolyzed protein are used in combination at the mass ratios within the above range, the composition can exhibit a more significant synergistic effect and can further synergistically relieve allergies and / or improve eczema.

[0040] In some embodiments, the composition may consist of medium- and long-chain fatty acid triglycerides and partially hydrolyzed protein, wherein the mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein may be 0.167:1 to 6:1, preferably 0.333:1 to 6:1, more preferably 0.667:1 to 6:1, and even more preferably 1:1 to 6:1.

[0041] In some embodiments, the product may include or be a drug.

[0042] In some embodiments, the drug may be any dosage form, such as a solid dosage form (granules, powders, tablets, etc.) or a liquid dosage form. Furthermore, those skilled in the art will readily understand that, depending on the dosage form and application scenario, the drug may also include various pharmaceutically permissible excipients.

[0043] The products, such as pharmaceuticals, can be prepared using methods commonly employed in the art, which will not be elaborated upon here.

[0044] In some embodiments, the content of the medium- and long-chain fatty acid triglycerides is 0.1% to 30% (dry weight) based on the total dry weight of the product. As an example, the content of the medium- and long-chain fatty acid triglycerides may be 0.1%, 0.2%, 0.5%, 0.8%, 1.0%, 2.0%, 3.0%, 4.0%, 5.0%, 6.0%, 7.0%, 8.0%, 9.0%, 10.0%, 11.0%, 12.0%, 13.0%, 14.0%, 15.0%, 16.0%, 17.0%, 18.0%, 19.0%, 20.0%, 21.0%, 22.0%, 23.0%, 24.0%, 25.0%, 26.0%, 27.0%, 28.0%, 29.0%, or 30.0% (dry weight), or within the range defined by any two of the above, based on the total dry weight of the product.

[0045] In some embodiments, the product may help relieve allergies and / or improve eczema. In some embodiments, the subjects (subjects) for relieving allergies and / or improving eczema are not particularly limited and may include, for example, infants, toddlers, children, adolescents, adults, young adults, middle-aged people, and / or the elderly. As used herein, the term “infant” refers to a person aged from birth to 12 months; the term “toddler” refers to a person aged 1 to 3 years; the term “child” refers to a person aged 3 to 7 years; the term “adolescent” refers to a person aged 7 to 17 years; the term “adult” refers to a person aged 18 years or older; the term “young adult” refers to a person aged 18 to 40 years; the term “middle-aged person” refers to a person aged 41 to 65 years; and the term “elderly person” or “senior person” refers to a person aged 65 years or older.

[0046] In some embodiments, the relief of allergies and / or improvement of eczema may include preventing allergies and / or eczema, or relieving one or more symptoms of allergies and / or eczema. For example, the relief of allergies and / or improvement of eczema may include reducing trypsin levels and relieving itching, or one or more of these.

[0047] Example

[0048] The present application will be more easily understood by referring to the following embodiments, which are only used to illustrate certain aspects and implementation methods of the present application and are not intended to limit the present application.

[0049] Unless otherwise stated, all materials used in this embodiment are commercially available or conventional materials.

[0050] laboratory animals

[0051] Zebrafish were raised in aquarium water at 28°C (water quality: 200 mg of readily soluble sea salt added per 1 L of reverse osmosis water; conductivity 450~550 μS / cm; pH 6.5~8.5; hardness 50~100 mg / L CaCO3), bred and provided by the fish farming center of Huante Biotechnology Co., Ltd. The laboratory animal use license number is: SYXK (Zhejiang) 2022-0004. The husbandry and management met the requirements of international AAALAC certification (certification number: 001458), and the IACUC ethics review number is: IACUC-2025-202510290008-01.

[0052] Instruments, consumables and reagents

[0053] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); Precision electronic balance (CP214, OHAUS, USA); 6-well plate (Zhejiang Beilanbo Biotechnology Co., Ltd., China); 96-well plate (Nest Biotech, China); Fully automatic rapid sample grinder (JXFSTPRP-24L, Shanghai Jingxin Laboratory Equipment Technology Department, China); High-speed refrigerated centrifuge (Heraeus Fresco17, ThermoFisher, Germany); Multifunctional microplate reader (SPARK, TECAN, Austria); Behavioral analyzer (Zebra Lab 3.22.3.31, Viewpoint, France).

[0054] Dimethyl sulfoxide (DMSO, batch number 20250624, Sinopharm Chemical Reagent Co., Ltd., China); PBS Phosphate Buffered Solution (dry powder) (lot number 20250730, Biosharp, China); Zebrafish trypsin (TPS) enzyme-linked immunosorbent assay kit (catalog number ml286418V, Shanghai Enzyme-Link Biotechnology Co., Ltd., China); BCA Protein Concentration Assay Kit (Batch No. 20F05A97, Boster Biological Engineering Co., Ltd., China); Medium- and long-chain triglycerides (MLCT) are derived from medium- and long-chain fatty acid edible oils (production batch number 20250804) supplied by Yihai Kerry, with a purity of 61%. Hydrolyzed protein: Partially hydrolyzed whey protein, derived from Hilmar PROtelyzeAdvance (degree of hydrolysis in the range of 7% - 15%) provided by Galaxy Ventures; Loratadine, tablets, supplied by Peking University Medicine Co., Ltd. (batch number 241203); 2,4-Dinitrochlorobenzene (DNCB) (Batch No. F2518064, Shanghai Aladdin Biochemical Technology Co., Ltd., China); In the following examples, the amounts and ratios of each component are based on the amount of the corresponding active ingredient. For example, partially hydrolyzed protein is based on the content of partially hydrolyzed protein in the partially hydrolyzed whey protein raw material; MLCT is based on the content of medium- and long-chain triglycerides in the long-chain fatty acid edible oil in the raw material.

[0055] Example I. Determination of the maximum detectable concentration of a single sample

[0056] Wild-type AB strain zebrafish were randomly selected 4 days after fertilization (4 dpf) and placed in 6-well plates with a volume of 3 mL per well. 30 zebrafish were treated.

[0057] Samples were administered in water (concentrations shown in Table 1), and a normal control group and a model control group were set up. Except for the normal control group, each experimental group was given water-soluble DNCB to establish a zebrafish eczema model. After treatment at 28°C for 21 h, except for the normal control group, each experimental group was given a high concentration of water-soluble DNCB and treated at 28°C for another 3 h. The maximum detectable concentration (MTC) of the sample in the model zebrafish was then determined. The results are shown in Table 1 below.

[0058] Table 1. Results of the MLCT maximum detection concentration (MTC) exploratory experiment (n = 30)

[0059] As shown in Table 1, under the experimental conditions, the MTC of MLCT was 2000 μg / mL, and the MTC of partially hydrolyzed proteins was 5000 μg / mL.

[0060] Example II. Evaluation of the efficacy of the sample in improving eczema (trypsin content)

[0061] 30 zebrafish were randomly selected from 4 dpf wild-type AB strains and placed in 6-well plates with a volume of 3 mL per well.

[0062] Water-soluble samples (concentrations shown in Table 2) were used as examples (MLCT + partially hydrolyzed protein) or comparative examples (single-component MLCT or single-component partially hydrolyzed protein); the positive control group was given loratadine at a concentration of 187.5 ng / mL; a normal control group (naïve, no treatment) and a model control group (eczema model, no drug administration) were also set up. Each group was set up in triplicate, and 90 zebrafish were used in each parallel experiment.

[0063] While administering the samples in water, all experimental groups except the normal control group received water-soluble DNCB to establish a zebrafish eczema model. After treatment at 28°C for 21 h, all experimental groups except the normal control group received water-soluble high-concentration DNCB. After further treatment at 28°C for 3 h, zebrafish samples from each group were collected according to the trypsin-like protein kit instructions. Data were collected using a multi-functional microplate reader to analyze the trypsin content in each group of zebrafish. The statistical analysis results of this index were used to evaluate the efficacy of the samples in improving eczema, especially in relieving allergies. Statistical results are expressed as mean ± standard error (SE). Statistical analysis was performed using SPSS software, and p < 0.05 was considered statistically significant.

[0064] For each embodiment and comparative example, the reduction in trypsin content compared to the model control group was calculated (denoted as A); and for each embodiment, the sum of the reductions in trypsin content compared to the model control group for the corresponding comparative example was calculated (denoted as B). For example, for Example 1 (MLCT 500 μg / mL + partially hydrolyzed protein concentration 3000 μg / mL), the "sum of reductions in trypsin content compared to the model control group for the corresponding comparative example" is the sum of the "reductions in trypsin content compared to the model control group" for Comparative Example 1 (MLCT concentration 500 μg / mL) and Comparative Example 6 (partially hydrolyzed protein concentration 3000 μg / mL). Finally, the synergy coefficient was calculated (denoted as C, C = A / B). When the synergy coefficient > 1, a synergistic effect exists; the higher the synergy coefficient (C) value, the stronger the synergistic effect.

[0065] Following the above method, zebrafish were administered partially hydrolyzed protein and MLCT at different ratios to evaluate their efficacy in improving eczema, particularly allergy relief. The dosages are shown in Table 2. The results are also shown in Table 2. Figure 1 As shown.

[0066] Table 2. Results of the experiment evaluating the efficacy of the samples in relieving allergies.

[0067] From Table 2 and Figure 1The results showed that, compared with the normal control group, the trypsin content of wild-type AB strain zebrafish in the model control group was significantly increased after induction with DNCB via water-soluble administration at 4 dpf. P <0.05) indicates that the DNCB-induced zebrafish eczema model was successfully established. The positive control group (loratadine), single-component partially hydrolyzed protein (333 μg / mL, 1000 μg / mL, and 3000 μg / mL), and Examples 1 to 7 (MLCT + partially hydrolyzed protein) all showed significant allergy-relieving effects, specifically demonstrated by a significant decrease in trypsin-like protein content compared to the model control group. P <0.05). That is, when the mass ratio of MLCT to partially hydrolyzed protein is 0.167-6, the combination of the two has the effect of relieving allergies.

[0068] For example, Example 1 is a combination of MLCT (500 μg / mL) and partially hydrolyzed protein (3000 μg / mL), wherein the mass ratio of MLCT to partially hydrolyzed protein is 0.167:1; Comparative Example 1 is a single-component MLCT (500 µg / mL); Comparative Example 6 is a single-component partially hydrolyzed protein. In other words, Example 1 is equivalent to a combination of Comparative Example 1 and Comparative Example 6. Compared with the model control group, the reduction in trypsin content in Example 1 was 1.44 ng / mg total protein; the reductions in trypsin content in Comparative Example 1 and Comparative Example 6 were 0.1 ng / mg total protein and 1.2 ng / mg total protein, respectively, with a sum of 1.3 ng / mg total protein. Therefore, the reduction in trypsin content in Example 1 is greater than the sum of the reductions in trypsin content in Comparative Example 1 and Comparative Example 6, indicating that Example 1 has a synergistic effect in alleviating allergies. Similarly, Examples 2 through 7 also demonstrated a synergistic effect in improving eczema, particularly in relieving allergies. That is, when MLCT was used in combination with partially hydrolyzed protein at a mass ratio ranging from 0.167:1 to 6:1, the two exhibited a synergistic effect in improving eczema, particularly in relieving allergies.

[0069] Furthermore, the synergistic effect can be further characterized by the synergistic coefficient. The synergistic coefficient reflects the strength of the synergistic effect of different doses of MLCT and partially hydrolyzed protein. The higher the synergistic coefficient, the more significant the synergistic effect of the corresponding dose combination. For example, Examples 1 to 7 all have satisfactory synergistic coefficients (> 1). In particular, the synergistic coefficient of Example 1 (MLCT / partially hydrolyzed protein = 0.167:1) is 1.108, indicating that Example 1 has a synergistic effect in relieving allergies; similarly, the synergistic coefficients of Examples 2 to 7 are all greater than 1, indicating that Examples 2 to 7 also have a synergistic effect in relieving allergies. Therefore, it is further shown that when MLCT and partially hydrolyzed protein are used in combination at a mass ratio of 0.167:1 to 6:1, there is a synergistic effect in improving eczema, especially in relieving allergies.

[0070] Furthermore, Examples 2 to 7 (MLCT / partially hydrolyzed protein mass ratio of 0.333:1 to 6:1) have a larger synergistic coefficient compared to Example 1 (MLCT / partially hydrolyzed protein = 0.167:1), indicating that the two have a more significant synergistic effect in improving eczema, especially in relieving allergies, at this mass ratio.

[0071] Furthermore, Examples 2, 3, and 5–7 (MLCT / partially hydrolyzed protein mass ratio of 0.667:1 to 6:1) have a larger synergistic coefficient compared to Examples 1 and 4 (MLCT / partially hydrolyzed protein mass ratios of 0.167:1 and 0.333:1, respectively), indicating that the synergistic effect of the two in improving eczema, especially in relieving allergies, is more significant at this mass ratio.

[0072] Furthermore, Examples 2, 3, 5, and 6 (MLCT to partially hydrolyzed protein mass ratio of 1:1 to 6:1) have a larger synergistic coefficient compared to Examples 1, 4, and 7 (MLCT to partially hydrolyzed protein mass ratios of 0.167:1, 0.333:1, and 0.667:1, respectively), indicating that the synergistic effect of the two on improving eczema, especially relieving allergies, is more significant at this mass ratio.

[0073] Example III. Evaluation of the efficacy of the sample in improving eczema (behavioral (pruritus))

[0074] 30 zebrafish were randomly selected from 4 dpf wild-type AB strains and placed in 6-well plates with a volume of 3 mL per well.

[0075] Water-soluble samples (concentrations shown in Table 3) were used as examples (MLCT + partially hydrolyzed protein) or comparative examples (single-component MLCT or single-component partially hydrolyzed protein); the positive control group was given loratadine at a concentration of 187.5 ng / mL; a normal control group (naïve, no treatment) and a model control group (eczema model, no administration) were also set up.

[0076] Except for the normal control group, each experimental group received water-soluble DNCB to establish a zebrafish eczema model. After treatment at 28°C for 21 h, each experimental group, except for the normal control group, received water-soluble high-concentration DNCB. After further treatment at 28°C for 3 h, 10 zebrafish from each experimental group were randomly selected and placed in a 96-well plate with a volume of 200 μL per well and one zebrafish per well. Behavioral data were collected for 20 min using a behavioral analyzer, and the total movement distance of the zebrafish was analyzed. The statistical analysis results of this index were used to evaluate the efficacy of the samples in improving eczema, especially in improving itching. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software, and p < 0.05 was considered statistically significant.

[0077] For each embodiment and comparative example, the reduction in total motion distance (mm) compared to the model control group was calculated (denoted as A); and for each embodiment, the sum of the reductions in total motion distance (mm) compared to the model control group for the corresponding comparative example was calculated (denoted as B). For example, for Example 1 (MLCT 500 μg / mL + partially hydrolyzed protein concentration 3000 μg / mL), the "sum of the reduction in total motion distance compared to the model control group for the corresponding comparative example" is the sum of the "reduction in total motion distance compared to the model control group" for Comparative Example 1 (MLCT concentration 500 μg / mL) and Comparative Example 6 (partially hydrolyzed protein concentration 3000 μg / mL). Finally, the synergy coefficient was calculated (denoted as C, C = A / B). When the synergy coefficient > 1, a synergistic effect exists; the higher the synergy coefficient (C) value, the stronger the synergistic effect.

[0078] Following the above method, zebrafish were administered partially hydrolyzed protein and MLCT at different ratios to evaluate their efficacy in improving eczema, particularly relieving itching. The dosages are shown in Table 3. The results are also shown in Table 3. Figure 2 and Figure 3 As shown.

[0079] Table 3. Experimental results evaluating the efficacy of the samples in improving eczema.

[0080] Note: Compared with the model control group, p < 0.05, p < 0.01, p < 0.001.

[0081] From Table 3 and Figure 2 The results showed that, compared with the normal control group, the total movement distance of wild-type AB strain zebrafish in the model control group was significantly increased after induction with DNCB via water-soluble administration at 4 dpf. P <0.05 indicates that the DNCB-induced zebrafish eczema model was successfully established. The positive control group (loratadine), single-component partially hydrolyzed protein (333 μg / mL, 1000 μg / mL, and 3000 μg / mL), and Examples 1-3 and 5-7 (MLCT + partially hydrolyzed protein) all significantly improved eczema, especially pruritus, specifically by a significant decrease in total movement distance compared to the model control group. P < 0.05).

[0082] For example, Example 1 was a combination of MLCT (500 μg / mL) and partially hydrolyzed protein (3000 µg / mL), wherein the mass ratio of MLCT to partially hydrolyzed protein was 0.167:1; Comparative Example 1 was a single-component MLCT (500 µg / mL); Comparative Example 6 was a single-component partially hydrolyzed protein (3000 µg / mL), i.e., Example 1 was relative to the combination of Comparative Examples 1 and 6. Compared with the model control group, the reduction in total movement distance in Example 1 was 1051 mm; the reductions in total movement distance in Comparative Examples 1 and 6 were 193 mm and 833 mm, respectively, and the sum of their reductions was 1026 mm. It is evident that the reduction in total movement distance in Example 1 was significantly greater than the sum of the reductions in total movement distance in Comparative Examples 1 and 4, indicating a synergistic effect of Example 1 in improving eczema. Similarly, Examples 2, 3, and 5–7 also showed a synergistic effect in improving eczema, especially in improving pruritus. That is, when MLCT is used in combination with partially hydrolyzed protein in a mass ratio ranging from 0.167:1 to 6:1, the two have a synergistic effect in improving eczema, especially in improving itching.

[0083] Furthermore, the synergistic effect can be further characterized by the synergistic coefficient. The synergistic coefficient reflects the strength of the synergistic effect of different doses of MLCT and partially hydrolyzed protein. The higher the synergistic coefficient, the more significant the synergistic effect of the corresponding dose combination. The synergistic coefficient of Example 1 is 1.024, indicating that Example 1 has a synergistic effect in improving eczema; similarly, the synergistic coefficients of Examples 2, 3, and 5–7 are also greater than 1, indicating that these examples also have a synergistic effect in improving eczema, that is, when MLCT and partially hydrolyzed protein are used in combination at a mass ratio ranging from 0.167:1 to 6:1, they have a synergistic effect in improving eczema, especially in improving itching.

[0084] Furthermore, Examples 2, 3, 5-7 (MLCT to partially hydrolyzed protein mass ratio of 0.667:1 to 6:1) have a larger synergistic coefficient than Example 1 (MLCT to partially hydrolyzed protein mass ratio of 0.167:1), indicating that the synergistic effect of the two on improving eczema, especially relieving itching, is more significant at this mass ratio.

[0085] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of this application, and are not intended to limit them. Although this application has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of this application.

Claims

1. Use of the composition in the preparation of a product for improving eczema, characterized in that, The composition comprises medium- and long-chain fatty acid triglycerides and partially hydrolyzed whey protein, wherein the mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed whey protein is from 0.167:1 to 6:1, and the degree of hydrolysis of the partially hydrolyzed whey protein is from 7% to 25%.

2. The use according to claim 1, characterized in that, The eczema mentioned is allergic eczema.

3. The use according to claim 1 or 2, characterized in that, The mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed whey protein is from 0.333:1 to 6:

1.

4. The use according to claim 1 or 2, characterized in that, The mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed whey protein is from 0.667:1 to 6:

1.

5. The use according to claim 1 or 2, characterized in that, The mass ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed whey protein is 1:1 to 6:

1.

6. The use according to claim 1 or 2, characterized in that, The degree of hydrolysis of the partially hydrolyzed whey protein is 7% to 17%.

7. The use according to claim 6, characterized in that, The degree of hydrolysis of the partially hydrolyzed whey protein is 7% to 15%.

8. The use according to claim 1 or 2, characterized in that, The improvement of eczema includes one or more of the following: reducing trypsin levels and relieving itching.

Images